Research Article| Volume 20, ISSUE 7, P952-963, July 2018

Download started.


Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy


      Background aims

      Adoptive cell therapy employing natural killer group 2D (NKG2D) chimeric antigen receptor (CAR)-modified T cells has demonstrated preclinical efficacy in several model systems, including hematological and solid tumors. We present comprehensive data on manufacturing development and clinical production of autologous NKG2D CAR T cells for treatment of acute myeloid leukemia and multiple myeloma ( Identifier: NCT02203825). An NKG2D CAR was generated by fusing native full-length human NKG2D to the human CD3ζ cytoplasmic signaling domain. NKG2D naturally associates with native costimulatory molecule DAP10, effectively generating a second-generation CAR against multiple ligands upregulated during malignant transformation including MIC-A, MIC-B and the UL-16 binding proteins.


      CAR T cells were infused fresh after a 9-day process wherein OKT3-activated T cells were genetically modified with replication-defective gamma-retroviral vector and expanded ex vivo for 5 days with recombinant human interleukin-2.


      Despite sizable interpatient variation in originally collected cells, release criteria, including T-cell expansion and purity (median 98%), T-cell transduction (median 66% CD8+ T cells), and functional activity against NKG2D ligand-positive cells, were met for 100% of healthy donors and patients enrolled and collected. There was minimal carryover of non–T cells, particularly malignant cells; both effector memory and central memory cells were generated, and inflammatory cytokines such as granulocyte colony-stimulating factor, RANTES, interferon-γ and tumor necrosis factor-α were selectively up-regulated.


      The process resulted in production of required cell doses for the first-in-human phase I NKG2D CAR T clinical trial and provides a robust, flexible base for further optimization of NKG2D CAR T-cell manufacturing.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gacerez A.T.
        • Arellano B.
        • Sentman C.L.
        How chimeric antigen receptor design affects adoptive T cell therapy.
        J Cell Physiol. 2016; 231: 2590-2598
        • Srivastava S.
        • Riddell S.R.
        Engineering CAR-T cells: design concepts.
        Trends Immunol. 2015; 36: 494-502
        • Dotti G.
        • Gottschalk S.
        • Savoldo B.
        • Brenner M.K.
        Design and development of therapies using chimeric antigen receptor-expressing T cells.
        Immunol Rev. 2014; 257: 107-126
        • Sadelain M.
        • Brentjens R.
        • Riviere I.
        The basic principles of chimeric antigen receptor design.
        Cancer Discov. 2013; 3: 388-398
        • Zhang H.
        • Ye Z.L.
        • Yuan Z.G.
        • Luo Z.Q.
        • Jin H.J.
        • Qian Q.J.
        New strategies for the treatment of solid tumors with CAR-T cells.
        Int J Biol Sci. 2016; 12: 718-729
        • Newick K.
        • Moon E.
        • Albelda S.M.
        Chimeric antigen receptor T-cell therapy for solid tumors.
        Mol Ther Oncolytics. 2016; 3: 16006
        • Waldhauer I.
        • Steinle A.
        NK cells and cancer immunosurveillance.
        Oncogene. 2008; 27: 5932-5943
        • Spear P.
        • Wu M.R.
        • Sentman M.L.
        • Sentman C.L.
        NKG2D ligands as therapeutic targets.
        Cancer Immun. 2013; 13: 8
        • Sentman C.L.
        • Meehan K.R.
        NKG2D CARs as cell therapy for cancer.
        Cancer J. 2014; 20: 156-159
        • Zhang T.
        • Lemoi B.A.
        • Sentman C.L.
        Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
        Blood. 2005; 106: 1544-1551
        • Almasbak H.
        • Aarvak T.
        • Vemuri M.C.
        CAR T cell therapy: a game changer in cancer treatment.
        J Immunol Res. 2016; 2016 (5474602)
        • Jena B.
        • Moyes J.S.
        • Huls H.
        • Cooper L.J.
        Driving CAR-based T-cell therapy to success.
        Curr Hematol Malig Rep. 2014; 9: 50-56
        • Maus M.V.
        • Grupp S.A.
        • Porter D.L.
        • June C.H.
        Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
        Blood. 2014; 123: 2625-2635
        • Lee D.W.
        • Kochenderfer J.N.
        • Stetler-Stevenson M.
        • Cui Y.K.
        • Delbrook C.
        • Feldman S.A.
        • et al.
        T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
        Lancet. 2015; 385: 517-528
        • Maude S.L.
        • Frey N.
        • Shaw P.A.
        • Aplenc R.
        • Barrett D.M.
        • Bunin N.J.
        • et al.
        Chimeric antigen receptor T cells for sustained remissions in leukemia.
        N Engl J Med. 2014; 371: 1507-1517
        • Porter D.L.
        • Hwang W.T.
        • Frey N.V.
        • Lacey S.F.
        • Shaw P.A.
        • Loren A.W.
        • et al.
        Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
        Sci Transl Med. 2015; 7: 303ra139
        • Davila M.L.
        • Riviere I.
        • Wang X.
        • Bartido S.
        • Park J.
        • Curran K.
        • et al.
        Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
        Sci Transl Med. 2014; 6: 224ra25
        • Torikai H.
        • Cooper L.J.
        Translational Implications for off-the-shelf immune cells expressing chimeric antigen receptors.
        Mol Ther. 2016; 24: 1178-1186
        • Ritchie D.S.
        • Neeson P.J.
        • Khot A.
        • Peinert S.
        • Tai T.
        • Tainton K.
        • et al.
        Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
        Mol Ther. 2013; 21: 2122-2129
        • Brudno J.N.
        • Somerville R.P.
        • Shi V.
        • Rose J.J.
        • Halverson D.C.
        • Fowler D.H.
        • et al.
        Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease.
        J Clin Oncol. 2016; 34: 1112-1121
        • Kochenderfer J.N.
        • Wilson W.H.
        • Janik J.E.
        • Dudley M.E.
        • Stetler-Stevenson M.
        • Feldman S.A.
        • et al.
        Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
        Blood. 2010; 116: 4099-4102
        • Barber A.
        • Sentman C.L.
        NKG2D receptor regulates human effector T-cell cytokine production.
        Blood. 2011; 117: 6571-6581
        • Bajgain P.
        • Mucharla R.
        • Wilson J.
        • Welch D.
        • Anurathapan U.
        • Liang B.
        • et al.
        Optimizing the production of suspension cells using the G-Rex “M” series.
        Mol Ther Methods Clin Dev. 2014; 1: 14015
        • Wang X.
        • Riviere I.
        Clinical manufacturing of CAR T cells: foundation of a promising therapy.
        Mol Ther Oncolytics. 2016; 3: 16015
        • Hollyman D.
        • Stefanski J.
        • Przybylowski M.
        • Bartido S.
        • Borquez-Ojeda O.
        • Taylor C.
        • et al.
        Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
        J Immunother. 2009; 32: 169-180
        • Singh N.
        • Perazzelli J.
        • Grupp S.A.
        • Barrett D.M.
        Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.
        Sci Transl Med. 2016; 8: 320ra3
        • Thomas S.N.
        Committing CAR T cells to memory.
        Sci Transl Med. 2016; 8: 370ec205
        • Kueberuwa G.
        • Gornall H.
        • Alcantar-Orozco E.M.
        • Bouvier D.
        • Kapacee Z.A.
        • Hawkins R.E.
        • et al.
        CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo.
        J Immunother Cancer. 2017; 5: 14
        • Klebanoff C.A.
        • Gattinoni L.
        • Restifo N.P.
        Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?.
        J Immunother. 2012; 35: 651-660
        • Golubovskaya V.
        • Wu L.
        Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy.
        Cancers (Basel). 2016; 8
        • Spear P.
        • Barber A.
        • Sentman C.L.
        Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.
        Oncoimmunology. 2013; 2: e23564
        • Spear P.
        • Barber A.
        • Rynda-Apple A.
        • Sentman C.L.
        Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF.
        J Immunol. 2012; 188: 6389-6398